Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central anxious technique, conolidine modulates alternate molecular targets. A Science Advances review identified that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://johnd951rjb7.wikimidpoint.com/user